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Abstract: To investigate a nuclear factor-kappa B decoy oligonucleotides strategy on the 
inhibition of tissue factor (TF) expression in cultured rat brain microvascular endothelial 
cells (BMECs) by polylactic acid (PLA) nanoparticles delivery system and to evaluate 
this new vector for in vitro gene therapy. Nanoparticles were formulated using poly 
D,L-polylactic acid with surface modifying by polysorbates 80. 3-[4,5- 
Dimethylthiazol-2,5-diphenyl-2H-tetrazolium bromide] (MTT) assays showed that PLA 
nanoparticles were not toxic to the cultured BMECs.The decoy oligonuceotides (ODNs) 
loaded within nanoparticles was 6 μg/mg, encapsulation efficacy was (60.5±1.5)%. It was 
observed by flow cytometry that the cellular uptake of nanoparticles depended on the 
time of incubation and the concentration of nanoparticles in the medium. And confocal 
microscopy demonstrated that nanoparticles localized mostly in the BMECs cytoplasm. 
The released decoy oligonuceotides (ODNs) uptaked by BMECs retained their biologic 
activity and led to reduced level of tissue factor expression as compared to control 
cultures. These findings offer a potential therapeutic strategy in the control of TF 
expression in BMECs in vitro and suggest that PLA nanoparticles may be appropriate as 
delivery vehicles for decoy strategy in the gene therapy of cerebral thrombosis. 
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Thrombosis plays a major role in the pathogenesis of ischemic stroke. Although some limited 
progress has been made in the treatment of cerebral thrombosis, current therapeutic options are still 
controversial because of a discouragingly high incidence of intracerebral hemorrhage and restenosis in 
treated patients [1-4]. Consequently, innovations for therapy of cerebral thrombosis have focused on 
selective and non-bleeding methods. 
Abnormal tissue factor (TF) expression on vascular endothelial cells may account for thrombotic 
events associated with cardiovascular and cerebrovascular disease [5-7]. In vitro, a variety of 
inflammatory stimuli and immunological mediators, including bacterial endotoxin (lipopolysaccharide, 
LPS), the tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), can change endothelial cells to a 
procoagulant state by inducing TF expression. 
TF expression in vascular endothelial cells exposed to LPS can be regulated at level of transcription 
[8]. The activation of transcription factor nuclear factor-kappa B (NF-κB) plays a key role in TF 
expression in damaged endothelial cells [9]. In recent studies, we have identified NF-κB transcription 
factor decoy (TFD) strategy, which is believed to be a powerful tool for anti-gene strategies and 
transcription regulation [10-12], and can inhibit TF over-expression in stimulated human umbilical 
vein endothelial cells (HUVEC) by disruption of NF-κB activation [13]. Therefore, the decoy 
approach may enable us to prevent cerebrovascular diseases once oligonuceotides (ODNs) was 
delivered into brain. 
Brain microvascular endothelial cells (BMECs) were important targets in gene therapies for 
cerebral thrombosis. We have reported that polysorbate 80 (Tween 80, T-80)-coated nanoparticles 
(NPs) can be used as drug delivery vehicle targeting brain vessels [14-15]. The mechanism suggests 
that drug-loaded NPs may be endocytosised by BMECs. Thus, the presence of this mechanism may 
provide an efficient way in the brain vascular endothelial cells targeting. 
In this study, we examined the ability of NF-κB decoy ODNs enveloped in polylactic acid (PLA) 
NPs to suppress TF gene expression in primary cultures of rat BMECs. The data offered a potential 
therapeutic strategy in the regulation of TF expression in BMECs in vitro and suggest that PLA NPs 
may be an appropriate delivery vehicle for decoy strategy in the gene therapy of cerebral thrombosis. 
2. Materials and methods 
2.1. Materials 
PLA (racemic, 5000 in molecular weight) was purchased from Institute of Medical Equipments of 
Shandong Province, P.R. China. Reagents were analysis-grade chemicals made in China, mainly 
including polyvinyl alcohol (PVA), cetyltrimethyl ammonium bromide (CTAB), dimethyl sulfoxide 
(DMSO) and paraformaldehyde. Endothelial cell growth supplement (ECGS), collagenase II, MTT Int. J. Mol. Sci. 2008, 9  
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and LPS were purchased from Sigma Chemical Company. Culture media Dulbecco’s Modified Eagle 
Media (DMEM), fetal bovine serum, penicillin-streptomycin, and Trizol Reagent were obtained from 
GIBCO-BRL, Life Technologies. Anti-p65 rabbit polyclonal antibody was obtained from Santa Cruz 
Biotechnology. Taq DNA polymerase and Moloney Murine Leukemia Virus (MMLV) reverse 
transcriptase 1-kb DNA ladder were from Promega Corporation. Neonate Wistar rats were supplied by 
the Experimental Animal Center of Tongji Medical College, Huazhong University of Science & 
Technology, Hubei, P.R. China. 
2.2. Culture of BMECs 
The method of primary culture of rat BMECs has been previously described [16,17]. In brief, 
cerebral microvessels were collected from neogenetic Wistar rats by homogenate and twice filtrations. 
Microvessels were dissociated with 0.2% collagenase II by steady shaking for 10min at room 
temperature. The endothelial cells were collected after differential centrifugation and filtering through 
nylon mesh, resuspended in the DMEM medium, and supplemented with 10 mmol/L Hepes, 20% fetal 
calf serum, 20 mg/L ECGS, 100 mg/L heparin, 100 unit/mL penicillin, and 100 μg/mL streptomycin. 
After filtrated through nylon mesh, BMECs were plated onto collagen coated Petri dishes for 4h, 
allowing for BMECs attachment to the collagen substrate. And then the media was removed. 
Afterward, the media was changed twice a week. 
2.3. Decoy design 
Upper-strand and reverse-complement phosphorothioated oligonucleotides were commercially 
synthesized, purified and annealed by Saibaisheng Inc. (Shanghai, China). ODNs used for the study 
were phosphorothioate-modified to reduce intracellular nuclease digestion. For fluorescence studies, 
ODNs were 5’-end-labeled with fluorescein isothiocyanate (FITC). Two ODNs sequences were 
synthesized and used. The NF- κB decoy ODNs has the same sequence with the κB site in TF 
promoter, which is 5’-GTCCCGGAGTTTCCTACCGGG-3’ with the consensus sequence underlined. 
In addition to the NF-κB decoy ODNs, a scrambled decoy was used as control for specificity. The 
sequence of scrambled decoy (M-decoy) was different from the κB site in the consensus sequence 
while the flanking sequence was the same, which is 5’-GTCCATCCTGGGATTACCGGG-3’. 
2.4. Formulation of PLA NPs containing NF-κΒ decoy ODNs 
Firstly, decoy ODNs were modified with the cationic surfactant CTAB to improve the lipophilicity. 
ODNs loaded PLA NPs were then prepared by a nanoprecipitation method [14, 18] with some 
modifications. Briefly, ODNs-CTAB was dissolved in DMSO and then slowly added into PLA 
solution. The pre-formed suspension was slowly dripped into 2.5% (wt/V) poly (vinyl alcohol) (PVA) 
solution where the ratio of DMSO to PVA was 1:4-1:6.6(V/V). Centrifuged the suspension three times 
to remove the DMSO and PVA. The fabricated NPs were finally collected, centrifuged, lyophilized to 
dryness, and stored at -70 ºC before use. The procedure was applied to both decoy and mutant ODNs. Int. J. Mol. Sci. 2008, 9  
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The initial total encapsulation amount measuring of ODNs-nanoparticles: ODNs-PLA NPs powder 
(decoy PLA NPs and M-decoy-PLA NPs, 20 mg) was dissolved in methylene dichloride (1 mL), kept 
in 37 ºC for 6 hours, PBS (1 mL) was added to the solution. Twnty four hours later, the ODNs was 
supposed to be resolved in the solution sufficiently and its concentration was measured by the 
fluorospectrophotometer. Experiments were performed in triplicate. 
2.5. Particle size analysis and zeta potential 
The morphology of PLA NPs loading ODNs was observed with atomic force microscopy (AFM) in 
the tapping mode. A drop of the suspension was dripped to the freshly cleaved mica and dried at room 
temperature. AFM observations were then done with a SPA 400 AFM (Seiko Instruments Industry Co., 
Ltd. Japan). The polydispersity index and the zeta potential of PLA NPs were measured in triplicate by 
a Zetasizer (Zeta Pals, Brookhaven Instruments, USA) at 15 ºC at a wavelength of 635.0 nm. 
2.6. Cellular toxicity of PLA nanoparticles: 
MTT assay was employed to evaluate the cellular toxicity of prepared PLA nanoparticles. The cells 
in exponential growth phase were seeded in a 96-well plate making sure that 1×10
5 cells were present 
in each well. PLA nanoparticles suspension was added to each well and the final concentration should 
be 1, 2, 5, 10, 20 μg/mL. The incubation duration for each concentration group should be 30 min, 1 h, 
2 h, 4 h, 8 h, 16 h, respectively. Each group should include 3 to 5 wells. 6 wells were taken as normal 
cell group and another 6 wells were taken as blank group (only cell culture fluid included).The plate 
was incubated at 37 °C in a humidified incubator, 5% CO2 for 48 hours. Then MTT reagent (5 mg/mL, 
20 µL) was added into each well and the plate was incubated at 37 °C for 4 hours. The the medium 
was removed and DMSO (200 µL) was added to each well. After 1 hour incubation, absorbance(A) at 
490 nm was measured using a plate reader.The cell growth inhibitory ratio was calculated via 
following formula and described with cell growth inhibitory curve. The half cell growth inhibitory 
concentration (IC50) was calculated with the curve. Cell Growth inhibitory ratio=[1 - (average 
absorbance of experimental group/average absorbance of contrast group)]×100%. 
 
2.7. Detection the uptake rate of PLA NPs loading ODNs in BMECs 
 
Confluent BMECs were digested by 0.02% EDTA plated into 24-well multidishes at a density of 
4×10
4 cells per well. Cells were kept in medium DMEM + 10% Fetal Bovine Serum (FCS) for 24 h at 
37 ºC, 5% CO2 before use. Columns accommodated the following formulations: (1) suspension of 
blank PLA NPs, (2) cell cultures exposed to 5 μmol/L ODNs in PBS solution, (3) cell cultures exposed 
to mixture of 5 μmol/L ODNs and PLA NPs, (4-6) cell cultures exposed to decoy ODNs loaded PLA 
NPs with ODNs concentration of 0.5, 2.5, and 5 μmol/L in medium. Row provided for 4 independent 
data points per iteration. One single array was harvested at each of 30 min, 60 min and 120 min time 
period. Cells were detached from culture plates with EDTA solution and washed twice with PBS. The 
percentage of FITC-positive cells was detected by flow cytometric analysis at a wavelength of 490 nm. Int. J. Mol. Sci. 2008, 9  
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2.8. Observation of cellular localization of ODNs loaded PLA NPs 
BMECs were plated into dishes in which have sterile slides and were maintained in medium as 
above described. The FAM labelled ODNs-PLA NPs were added for 1 h after replating. The control 
cells were incubated with NPs without ODNs. Then medium was removed and acetone was added to 
fix the cells. Slides were washed three times with PBS and observed under confocal microscope. The 
excitation wave and emission wave of optical filter were 490 nm and 520 nm respectively. 
2.9. Expression of TF mRNA in BMECs induced by NF- κB decoy ODNs loaded PLA NPs 
BMECs were plated in 24-well arrays of 4-row × 6-column. Columns accommodated the following 
formulations: (1) suspension of blank NPs, (2) cell cultures exposed to 5 μmol/L NF-κB decoy ODNs 
in PBS solution, (3) cell cultures exposed to M-decoy ODNs loaded PLA NPs with ODNs 
concentration of 0.5 μmol/L, (4) cell cultures exposed to NF-κB decoy ODNs loaded PLA NPs with 
ODNs concentration of 0.5 μmol/L, (5) cell cultures exposed to mixture of 0.5 μmol/L ODNs and PLA 
NPs, (6) control of blank. Row provided for 4 independent data points per iteration. ODNs were added 
6 h after re-plating and maintained for 1 h before LPS (1 μg/mL) was added in. 
The mRNA expressions of TF and glyceraldehydes phosphate dehydrogenase (GAPDH) in BMECs 
were semiquantitatively detected by reverse transcription-polymerase  chain reaction (RT-PCR). 
BMECs were collected after exposed to LPS for 2 h. Total RNA was then isolated from untreated 
control cells, cells stimulated with LPS, and decoy-transferred cells, respectively, by utilization of the 
TRIZOL reagent following the manufacturer’s instructions (Gibco). 10 to 12 μg of total RNA could be 
yielded from 5×10
5 cells. RNA samples were diluted to a final concentration of 1μg/μL in RNase-free 
water and stored at -80 ºC until use. Synthesis of cDNA was performed with 1 μg of total RNA. The 
20×RT reaction consisted of 5× firststrand buffer, 0.5 mmol/L dNTP, 50 nmol/L random primers, and 
20 U Superscript reverse transcriptase (all reagents from Promega, Madison, Wisconsin, USA). PCR 
reaction was carried out with specific primers. For TF, the sense primer was 5’-CTA CTG TTT CAG 
TGT TCA AGC AGT GA-3’ and the antisense primer was 5’-CAG TGC AAT ATA GCA TTT GCA 
GTA GC-3’, with an amplified product of 283bp. For GAPDH, the sense primer was 5’-CAA AGT 
TGT CAT GGA TGA CC-3’and the antisense primer was 5’-CAA TGG AGA AGG CTG GGG-3’, 
with an amplified product of 195bp. PCR reaction was performed with 30 cycles, with denaturation at 
94 ºC for 45 s, annealing at 58 ºC for 45 s and extension at 72 ºC for 45 s. At the end of these cycles, a 
further extension was carried out at 72 ºC for 10 min. Negative controls as no cDNA or no RTase in 
the reaction were used to make sure that there was no artificial amplification and to exclude 
amplification of genomic DNA. The PCR products were separated on a 1% agarose gel containing 
0.01% ethidium bromide and the intensities of the stained bands were quantitated by densitometric 
analysis. DNA ladder was employed as the DNA marker. The amount of TF mRNA was normalized 
relative to the GAPDH mRNA. 
2.10. Nuclear protein P65 in BMECs induced by decoy ODNs NPs 
Western blot analyses were performed in order to investigate the level of P65 in nuclear of BMECs. 
BMECs were grouping and disposed as described in method 2.9. Nuclear protein was extracted Int. J. Mol. Sci. 2008, 9  
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according to the procedure of the kit (Pierce Biotechnology) after BMECs were exposed to LPS for 5h. 
Protein concentration was measured by bicinchoninic acid (BCA) method. Thereafter, 15μL extracted 
proteins were diluted in Laemmli sample buffer, denatured at 90 ºC for 5 min, separated on 12% 
SDS-PAGE gels at 150 V for 45 min, and transferred to polyvinylidene difluoride (PVDF) membranes. 
Following transfer, PVDF membranes were incubated in blocking solution [Tris-buffered
  saline 
containing 5% (w/v) skim milk powder and 0.5% (v/v) Tween
 20] for 2h at room temperature. 
Membranes
 were incubated with primary antibodies diluted in blocking solution
 overnight at 4 ºC. 
Following primary incubation, membranes were
 washed three times in blocking solution and incubated 
for 1h
 with horseradish peroxidase-conjugated anti-IgG (Bio-Rad). A final
 wash over 30min with six 
changes in wash buffer (Tris-buffered
  saline containing 0.5% Tween 20) was performed. 
Immunoreactive
 bands were finally visualized by autoradiography using enhanced chemiluminescence
 
(ECL) with exposure time of 30s to 2min. Densitometry was performed using Kodak EDAS 1D image 
analysis
 software. 
2.11. Statistic analysis 
The results were given as mean ± standard deviation. Data were stored and analyzed by the software 
package SPSS 11.5. Differences in means of normally distributed data were assessed by Student’s t test 
with Bonferroni correction. A P value less than 0.05 is considered significantly. 
3. Results 
3.1. Physical Characteristic of decoy ODNs loaded PLA NPs 
The PLA NPs produced were uniform spherical particles with an effective diameter of 162.1 nm and 
a polydispersity index of 0.118 (Figure 1, Figure 2). The average surface zeta potentials of decoy 
ODNs NPs was 0.21 mV. Compared with blank PLA-NPs, which had a average zeta potentials of 
-17.37 mV, the zeta potentials of decoy ODNs NPs increased by 17.58 mV, suggesting that decoy 
ODNs were bound to PLA NPs, and the surface hydrophilicity of PLA NPs was obviously enhanced. 
Figure 1. AFM image of PLA-NPs loading decoy ODNs. 
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Figure 2. Size distribution of SFNPs: — density distribution and −− cumulative 
distribution. 
 
The initial total encapsulation amount of decoy-ODNs in NPs is 6 μg/mg,which is measured by 
spectrophotofluorometer.The corresponding encapsulation ratio is (60.5±1.5)% equivalently 
encapsulation. 
3.2. MTT result 
As Table 1 showed.The growth inhibitory ratios of BMECs by PLA NPs were very low, the highest 
was 8.4±1.8% with the corresponding concentration 20 μg/mL. There is a rising tendency of the 
BMECs growth inhibitory ratios when the working concentration increased. Analysis of variance 
showed in the same working duration, 1, 2, 5, 10 μg/mL concentration groups differed from each other 
significantly. The above results showed cytotoxicity of PLA on BMECs was very low. The cell growth 
inhibitory ratio didn’t increase when the working duration prolonged.These initial results showed 
rather high bioseurity of PLA. 





30min 1h 2h 4h 8h  16h 
1  1.5±0.8  1.8±1.7 2.5±1.2 1.8±1.0 1.6±1.2  1.6±1.1 
2  1.8±1.1  1.7±1.2 2.0±1.4 2.1±0.9 1.9±1.6  1.8±2.1 
5  3.6±1.5  2.7±1.5 2.5±1.2 2.8±1.2 2.0±1.9  1.9±1.6 








# Comparison of cell growth inhibitory ratio between different working concentration in the same 
column of incubation time, p<0.05. Int. J. Mol. Sci. 2008, 9  
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3.3. PLA NPs based strategies for decoy ODNs delivery into BMECs 
Decoy ODNs could be introduced efficiently into BMECs with the encapsulation of PLA NPs. 
NF-κΒ decoy ODNs encapsulated by PLA NPs (Group 4, 5, 6) found in BMECs by flow cytometry 
increased significantly compared to other control groups (Group 1, 2, 3 ; P<0.01, Figure 3). It was 
observed that there was bright green fluorescence in cytoplasma of BMECs exposed to decoy ODNs 
loaded PLA NPs (Figure 4A), while no fluorescence was seen in control cells exposed to PLA NPs 
without ODNs (Figure 4B). 
Figure 3. The efficiency of uptake of nanoparticles by BMECs in six varying groups. (1) 
blank PLA nanoparticles; (2) FITC labeled decoy ODNs in PBS; (3) mixture of decoy 
ODNs and PLA nanoparticles; (4) decoy ODNs-loaded nanoparticls in three varying 
concentrations (0.5, 2.5, and 5μΜ in culture medium). 
 
Figure 4. (A) Location of decoy-PLA nanoparticlesuptaked by BMECs in cytoplasma; (B) 
control cells were incubated with NPs without ODNs. 
 
 Int. J. Mol. Sci. 2008, 9  
 
1859
3.4. Effect of NF-κΒ decoy ODNs loaded PLA NPs on the expression of TF mRNA in BMECs 
Two hours after 1μg/mL LPS stimulation, TF mRNA levels were clearly increased (Lane 6 in 
Figure 5) than BMECs without stimulation (Lane 7 in Figure 5). In BMECs exposed to NF-κΒ decoy 
ODNs loaded PLA NPs, a significant reduction in TF mRNA was observed (Lane 4). In contrast, 
disposal with mutant decoy ODNs or PLA NPs alone had no effect on the expression of TF mRNA 
(Lane 1, 2, 3, 5) compared to TF mRNA level in BMECs exposed to LPS (Lane 6). 
Figure 5. Expression of TF mRNA in BMECs stimulated by LPS exposed to different 
decoy-PLA nanoparticles. (1) blank PLA nanoparticles were added; (2) 0.5 μΜ decoy 
ODNs in PBS were added; (3) PLA nanoparticles loading 0.5μΜ M-decoy were added; (4) 
PLA nanoparticles loading 0.5 μΜ NF-κΒ decoy ODNs were added; (5) mixture of decoy 
ODNs and PLA nanoparticles were added; (6) blank control:no nanoparticles were added; 
(7) BMECs without LPS stimulation. 
 
 
3.5. Effect of NF-κΒ TFD ODNs loaded PLA NPs on the level of P65 in nuclear of BMECs 
Western blot analysis showed that P65 level in nuclear of BMECs, which were treated with LPS in 
the presence of decoy loaded PLA NPs, was significant lower than other groups (Figure 6). 
4. Discussions 
The strategy of cis decoy ODNs could regulate endogenous transcription of genes by binding or 
trapping transcription factors to deprive their functions. It becomes a new therapeutic method and a 
useful tool in the study of transcription regulation. In previous study, E2F decoy has been employed 
successfully in preventing intima hyperplasy of patients who had vein transplantation [19]. The decoy 
strategy in our study is to design a piece of oligonucleotide which has the same core sequence with the 
binding sites of cis element κΒ (5’CGGAGTTTCC 3’) in the promoter of TF. Binding of liberated 
NF-κΒ to phosphorothioated decoy deca-nucleotide elements within the cytoplasm prevents DNA 
binding and transactivation by the transcription factor of TF. It has been demonstrated that NF-κΒ Int. J. Mol. Sci. 2008, 9  
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decoy can obviously inhibit TF expression in endothelial cells stimulated by inflammatory factors and 
decrease the level of activated coagulation factor VII(FVIIa) by preventing activation of FVII 
indirectly. Thus, the hypercoagulable state (e.g. angina) may be retrieved and thrombogenesis may 
be diminished. 
Figure 6. The change of content of P65 in BMECs nuclear extracts by preincubation with 
decoy-PLA nanoparticles. (1) blank PLA nanoparticles; (2) 0.5μΜ decoy ODNs; (3) 
M-decoy loaded PLA nanoparticles with 0.5μΜ M-decoy; (4) decoy-PLA nanoparticles 




It is probable that such molecular therapeutic strategies will involve local delivery of NF-κΒ decoy 
ODNs. Even if a potential therapy is effective, it may not work because appropriate delivery has not 
been achieved. Though there are various vectors for transporting decoy ODNs, such as liposome and 
polycation delivery system, none of them can achieve for requisition of therapy of cerebrovascular 
diseases. Our work showed that the delivery system manufactured by polylactic acid nanoparticels 
could target cerebrovascular endothelial cells in animal experiments. For degradation products from 
PLA in bodies are carbon dioxide (CO2) and H2O [20], both with no harmful effects on organisms, 
PLA nanoparticle delivery system provides a method for gene therapy of cerebrovascular diseases  
in future. 
Decoy ODNs must be condensed and encapsulated in nanoparticels before transported into cells. A 
major advantage of the modified nanoprecipitation method is the avoidance of violent stirring for long 
time to disperse the microparticles. Such a method can take more advantage in keeping the structure 
and activity of biomacromolecule than the method of emulsify-solvent volatilixation [21, 22]. To avoid 
strong mechanical action and poison solvent, decoy ODNs were modified with the cationic surfactant 
CTAB to improve the lipophile. Modified ODNs showed some positive charge, but the surface of 
ODNs loaded PLA NPs was nearly electroneutral and the zeta potentials were much higher than PLA 
NPs without ODNs loading. We also measured that the entrapment efficiency of ODNs was 60.5 ± 1.5. 
These findings indicate that a large amount of double-strand ODNs have incorporated to PLA NPs. 
Moreover, the PLA NPs we prepared were uniform spherical particles observed by AFM. These 
characteristics manifest that PLA NPs are appropriate as delivery vehicles for transporting ODNs into 
target cells. Int. J. Mol. Sci. 2008, 9  
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BMECs are important target cells in the study of gene therapy for cerebrovasular diseases. It has 
been proved that NF-κΒ decoy ODNs could suppress TF expression in HUVECs in our previous study. 
In the present work, the level of TF mRNA in BMECs, uptaking NF-κΒ decoy ODNs loaded PLA NPs, 
was obviously lower than other control cultures. Furthermore, nuclear expression of NF-κΒ was found 
reducting significantly compared to control groups. These results provide the following evidence: (1) it 
is similar in cultured BMECs as other endothelial cells that TF is over expression when cells were 
stimulated by LPS; (2) NF-κΒ decoy ODNs released from those PLA NPs entering into BMECs were 
protected from degradation and remained biologically active and could inhibit TF expression. 
5. Conclusions 
Our results suggest that the molecular approach is effective in vitro to inhibit over-expression of TF 
in LPS stimulated BMECs and appropriate as delivery vehicles for NF-κΒ decoy ODNs. Further 
investigation on the application of PLA NPs loading ODNs for gene therapy in vivo are ongoing. The 
NF-κΒ decoy loaded nanoparticle will take an important role in the gene therapy and would provide a 
new method for treatments of cerebrovascular and other hypercoagulable diseases. 
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